Annexon, Inc.
ANNXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeAnnexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Valued at $923.3M, ANNX is a small-cap name in its sector. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis.
Market Cap
$923.3M
Beta
1.22
P/E (TTM)
—
P/E (Fwd)
-4.50
EPS (TTM)
$-1.13
EPS (Fwd)
$-1.08
ROE
-105.3%
ROA
-51.5%
Cash
$209.2M
Total Debt
$24.7M
Free CF
-$116.0M
52W Change
120.4%
Annual Financials
Cash vs Debt
Where ANNX stands vs its 150-day and 200-day moving averages
As of the August 26, 2026 close, ANNX finished 7.04% below its 150-day moving average ($5.54) and 3.01% below its 200-day moving average ($5.31). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ANNX overbought or oversold?
At the August 26, 2026 close, ANNX's RSI(14) was 43.4, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $209.2M in cash comfortably exceeding the $24.7M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$116.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -105.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With cash comfortably exceeding debt, ANNX has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Annexon, Inc. and its sector.